Intravenous Immunoglobulin Induced Transaminitis

Intravenous immunoglobulin (IVIG) is a common therapeutic modality used in immune-mediated neuropathy. While the therapeutic benefits are well known, adverse reactions have been reported. One such adverse event, though rare, is transaminitis, which appears to be a transient and a self-limiting adver...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) CA), 2023-12, Vol.15 (12), p.e51347
Main Authors: Vijaya Prakash, Aviraag, Parvathaneni, Aparna, Malempati, Sarat, Keilson, Gary
Format: Article
Language:English
Subjects:
Allergy/Immunology
Biopsy
Enzymes
Hospitals
Hyponatremia
Immunoglobulins
Internal Medicine
Liver
Metabolism
Neurology
Thyroid gland
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Intravenous immunoglobulin (IVIG) is a common therapeutic modality used in immune-mediated neuropathy. While the therapeutic benefits are well known, adverse reactions have been reported. One such adverse event, though rare, is transaminitis, which appears to be a transient and a self-limiting adverse reaction. Though most of the cases implicate the stabilizing agent to be the culprit, the exact mechanism is unknown. Thus far, it has been speculated that maltose, which has been commonly used as a stabilizer, is the cause of IVIG transaminitis. We present a unique case of a patient who developed transaminitis post-IVIG in which glycine was used as a stabilizing agent. We aim to draw a potential association between IVIG therapy and the development of transaminitis, thereby providing insight into the underlying mechanisms, as well as clinical features, and possibly encouraging further research on this topic.
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.51347